Literature DB >> 17414639

Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.

David Murdoch1.   

Abstract

(1) Head and neck squamous cell carcinoma is the sixth most frequently occurring cancer worldwide.(2) Chemotherapy has shown some success as part of multimodal treatment schedules for locally advanced, nonmetastatic head and neck squamous cell carcinoma, and too a much lesser extent for metastatic head and neck squamous cell carcinoma.(3) A recent meta-analysis of 32 studies involving >10,000 patients concluded that chemotherapy added to radiotherapy produces a large survival advantage relative to radiotherapy alone.(4) Concurrent or alternate chemoradiotherapy, with a schedule based on cisplatin, has an established place in the management of locally advanced nonmetastatic head and neck squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17414639     DOI: 10.1097/01.cco.0000264952.98166.99

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  22 in total

1.  XPF expression correlates with clinical outcome in squamous cell carcinoma of the head and neck.

Authors:  Alec Vaezi; Xiaozhe Wang; Shama Buch; William Gooding; Lin Wang; Raja R Seethala; David T Weaver; Alan D D'Andrea; Athanassios Argiris; Marjorie Romkes; Laura J Niedernhofer; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

2.  Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells.

Authors:  Marianne E Marshall; Trista K Hinz; Scott A Kono; Katherine R Singleton; Brady Bichon; Kathryn E Ware; Lindsay Marek; Barbara A Frederick; David Raben; Lynn E Heasley
Journal:  Clin Cancer Res       Date:  2011-06-14       Impact factor: 12.531

3.  Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate.

Authors:  Catherine M E Barnett; Natasa Broit; Pei-Yi Yap; Jason K Cullen; Peter G Parsons; Benedict J Panizza; Glen M Boyle
Journal:  Invest New Drugs       Date:  2018-04-18       Impact factor: 3.850

4.  PTK2/FAK: a new predictive biomarker for response to radiotherapy in head and neck squamous cell carcinoma.

Authors:  Emma J de Ruiter; Stefan M Willems
Journal:  Ann Transl Med       Date:  2016-10

5.  Hyperphosphorylation of replication protein A in cisplatin-resistant and -sensitive head and neck squamous cell carcinoma cell lines.

Authors:  Karoline C Manthey; Jason G Glanzer; Diana D Dimitrova; Greg G Oakley
Journal:  Head Neck       Date:  2010-05       Impact factor: 3.147

6.  Effect of radiotherapy on expression of hyaluronan and EGFR and presence of mast cells in squamous cell carcinoma of the head and neck.

Authors:  Eva Lindell Jonsson; Karin Nylander; Lars Hallén; Göran Laurell
Journal:  Oncol Lett       Date:  2012-09-11       Impact factor: 2.967

7.  A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines.

Authors:  Katherine R Singleton; Jihye Kim; Trista K Hinz; Lindsay A Marek; Matias Casás-Selves; Clark Hatheway; Aik Choon Tan; James DeGregori; Lynn E Heasley
Journal:  Mol Pharmacol       Date:  2013-01-31       Impact factor: 4.436

8.  [Treatment of advanced penile cancer. Do we need new methods for chemotherapy?].

Authors:  C Protzel; H-J Klebingat; O W Hakenberg
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

9.  1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.

Authors:  Yingyu Ma; Wei-Dong Yu; Pamela A Hershberger; Geraldine Flynn; Rui-Xian Kong; Donald L Trump; Candace S Johnson
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

10.  ERCC1 and XRCC1 as biomarkers for lung and head and neck cancer.

Authors:  Alec Vaezi; Chelsea H Feldman; Laura J Niedernhofer
Journal:  Pharmgenomics Pers Med       Date:  2011-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.